V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Rhythm Pharmaceuticals Executive Compensation (FY25)

RYTM · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
David Meeker
Latest say-on-pay support
=
June 24, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Rhythm Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): June 25, 2026
11 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Rhythm Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
362 figures on this page: 356 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — David Meeker: $14,663,742 → $17,544,525 (19.6% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Rhythm Pharmaceuticals' chief executive and what were they paid?
David Meeker was paid $17,544,525 in total compensation as Chairman of the Board, President and Chief Executive Officer for fiscal 2025. Meeker's total was 19.6% higher than the $14,663,742 reported for fiscal 2024.
What was Rhythm Pharmaceuticals' say-on-pay result?
Shareholders supported the say-on-pay proposal with 81.4% of votes cast including abstentions in favor at the meeting held June 24, 2026 for fiscal 2025.
Which companies are in Rhythm Pharmaceuticals' peer group?
Companies named in the disclosed peer group include Agios Pharmaceuticals, Amicus Therapeutics, Apellis Pharmaceuticals, Ardelyx and BioCryst Pharmaceuticals, among others.
What is Rhythm Pharmaceuticals' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 36:1, against median employee compensation of $484,876.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Meeker
Chief Executive Officer
◇——◇◇—◇◇
Hunter Smith
Chief Financial Officer
◇—◇◇◇—◇◇
Yann Mazabraud
Executive Vice President, Head of International
◇—◇◇◇—◇◇
Jennifer Chien
Executive Vice President, Head of North America
◇—◇◇◇—◇◇
Joseph Shulman
Chief Technical Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Meeker
Chief Executive Officer
◇—◇◇◇—◇◇
Hunter Smith
Chief Financial Officer
◇—◇◇◇—◇◇
Jennifer Lee
Executive Vice President, Head of North America
◇—◇◇◇—◇◇
Yann Mazabraud
Executive Vice President, Head of International
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Meeker
Chief Executive Officer
◇—◇◇◇—◇◇
Yann Mazabraud
Executive Vice President, Head of International
◇—◇◇◇—◇◇
Hunter Smith
Chief Financial Officer
◇—◇◇◇—◇◇
Jennifer Lee
Executive Vice President, Head of North America
◇—◇◇◇—◇◇
Joseph Shulman
Chief Technical Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Meeker
Chairman of the Board, President and Chief Executive Officer
◇—◇◇◇—◇◇
Hunter Smith
Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Yann Mazabraud
Executive Vice President, Head of International
◇—◇◇◇—◇◇
Jennifer Lee
Executive Vice President, Head of North America
◇—◇◇◇—◇◇
Alastair Garfield
Chief Scientific Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Alastair GarfieldRSU◇——◇——◇
Alastair GarfieldPSU◇—◇—◇—◇
Alastair GarfieldOPTION◇——◇—◇◇
David P. MeekerRSU◇——◇——◇
David P. MeekerPSU◇—◇—◇—◇
David P. MeekerOPTION◇——◇—◇◇
Hunter C. SmithRSU◇——◇——◇
Hunter C. SmithOPTION◇——◇—◇◇
Hunter C. SmithPSU◇—◇—◇—◇
Jennifer LeePSU◇—◇—◇—◇
Jennifer LeeRSU◇——◇——◇
Jennifer LeeOPTION◇——◇—◇◇
Yann MazabraudOPTION◇——◇—◇◇
Yann MazabraudPSU◇—◇—◇—◇
Yann MazabraudRSU◇——◇——◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Jennifer LeeRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇11/9/2030
RSU◇◇——
Option◇—◇02/1/2033
Option◇—◇02/11/2031
Option◇—◇02/14/2035
Option◇—◇02/9/2032
Option◇—◇02/16/2034
David MeekerRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/14/2035
RSU◇◇——
Option◇—◇02/7/2027
Option◇—◇06/06/2028
Option◇—◇06/19/2029
Option◇—◇06/17/2030
Option◇—◇07/17/2030
Option◇—◇02/9/2032
Option◇—◇02/11/2031
Option◇—◇02/01/2033
Option◇—◇2/16/2034
Yann MazabraudRSU◇◇——
Option◇—◇02/11/2031
RSU◇◇——
Option◇—◇02/9/2032
RSU◇◇——
RSU◇◇——
Option◇—◇10/5/2030
Option◇—◇02/16/2034
Option◇—◇02/14/2035
Hunter SmithRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇02/11/2031
RSU◇◇——
Option◇—◇07/17/2030
Option◇—◇2/16/2034
Option◇—◇02/9/2032
Option◇—◇02/14/2028
Option◇—◇02/13/2029
Option◇—◇02/14/2035
Option◇—◇02/14/2030
Option◇—◇02/1/2033
Alastair GarfieldRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/14/2035
Option◇—◇07/8/2034
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Alastair Garfield
Chief Scientific Officer · Offer letter · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
David Meeker
Chairman of the Board, President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Hunter Smith
Chief Financial Officer and Treasurer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Jennifer Lee
Executive Vice President, Head of North America · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Yann Mazabraud
Executive Vice President, Head of International · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance cash amount◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Edward T. Mathers
◇◇◇———◇
David W. J. McGirr
◇◇◇———◇
Lynn A. Tetrault
◇◇◇———◇
Camille Bedrosian
◇◇◇———◇
Stuart A. Arbuckle
◇◇◇———◇
Christophe R. Jean
◇◇◇———◇
Jennifer Good
◇◇◇———◇
Kimberly J. Popovits and David P. Meeker served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options and RSUs.
Stock ownership guideline: Under the Stock Ownership Policy, directors and executive officers subject to the Stock Ownership Policy have five years to come into compliance with the policy.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agios Pharmaceuticals AGIO
  • Amicus Therapeutics FOLD
  • Apellis Pharmaceuticals APLS
  • Ardelyx ARDX
  • BioCryst Pharmaceuticals BCRX
  • Blueprint Medicines Corporation BPMC
  • BridgeBio Pharma, Inc. BBIO
  • Catalyst Pharmaceuticals, Inc. CPRX
  • Insmed Incorporated INSM
  • Intra-Cellular Therapies ITCI
  • Ironwood Pharmaceuticals IRWD
  • Krystal Biotech, Inc. KRYS
  • Mirum Pharmaceuticals, Inc. MIRM
  • Ocular Therapeutix OCUL
  • PTC Therapeutics, Inc. PTCT
  • SpringWorks Therapeutics SWTX
  • TG Therapeutics TGTX
  • Travere Therapeutics TVTX
  • Ultragenyx Pharmaceuticals RARE
  • Vericel Corporation VCEL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 24, 2026=◇◇◇
2024June 25, 2025=◇◇◇
2023September 18, 2024=◇◇◇
2022June 21, 2023=◇◇◇
2021June 8, 2022=◇◇◇
2020June 9, 2021=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- David Meeker (Chairman of the Board, President and Chief Executive Officer), FY2025 total compensation $17,544,525 (base salary $807,692) [exec_comp, SEC accession 0001628280-26-028375, filed 2026-04-29]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Rhythm Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Rhythm Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Rhythm Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Rhythm Pharmaceuticals' disclosed peer group is defensible, who names Rhythm Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
362 figures on this page: 356 cited to the filing that reported them, 6 calculated from figures it prints.
356 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001628280-26-045569
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001628280-26-028375
    2025 Summary Compensation Table · Compensation Discussion and Analysis · DIRECTOR COMPENSATION
  3. 0001558370-25-008924
  4. 0001558370-25-005818
    2024 Summary Compensation Table
  5. 0001104659-24-101393
  6. 0001104659-24-052915
    2023 Summary Compensation Table
  7. 0001104659-23-073809
  8. 0001104659-23-051469
  9. 0001104659-22-070152
  10. 0001104659-21-080758
  11. 0001628280-26-012399
    Exhibit
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Rhythm Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/RYTM (accessed 2026).
Short form: data: Velarion

The Rhythm Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Rhythm Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Rhythm Pharmaceuticals discloses

The companies named in RYTM's own disclosed peer group.

Agios PharmaceuticalsAmicus TherapeuticsApellis PharmaceuticalsArdelyxBioCryst PharmaceuticalsBlueprint Medicines CorporationBridgeBio Pharma, Inc.Catalyst Pharmaceuticals, Inc.Insmed IncorporatedIntra-Cellular TherapiesIronwood PharmaceuticalsKrystal Biotech, Inc.Mirum Pharmaceuticals, Inc.Ocular TherapeutixPTC Therapeutics, Inc.SpringWorks TherapeuticsTG TherapeuticsTravere TherapeuticsUltragenyx PharmaceuticalsVericel Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy